Data & Analytics
IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza
The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.
A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."
Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.
Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
The latest data shows an overall widening of the US.
The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.
A study indicates consumers stop using them at the six-month mark.
Half-measures, like diabetes educational materials without a part B, fared poorly.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
Generics made up almost 75% of prescriptions in the United Kingdom last year.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.
Prices for some generics are rising, thanks to limited competition.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.